Chuikyo Approves Pfizer’s Selzentry And Janssen Pharma’s Intelence For NHI Listing
This article was originally published in PharmAsia News
Executive Summary
Japan's Central Medical Social Insurance Association (Chuikyo) approved Jan. 14 and listed the price for two HIV antiviral drugs, Pfizer's Selzentry (maraviroc) and Janssen Pharma's Intelence (etravirine). For maraviroc, indicated to treat patients with CCR5-tropic HIV-1 detectable who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents, Chuikyo set the price of ¥2,278.80 per tablet. Designated as an orphan drug, etravirine 100mg was set at ¥619.8 per tablet and a one-day dosage expense of ¥2,478.20. (Click here for more - Japanese language
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.